New drug combo aims to boost response in Hard-to-Treat colorectal cancer
NCT ID NCT07683403
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This trial investigates whether adding the drug savolitinib to standard chemotherapy plus cetuximab improves tumor shrinkage in people with a specific genetic subtype (RAS/BRAF wild-type) of metastatic colorectal cancer that has not been treated before. Participants are randomly assigned to receive either the three-drug combination or standard therapy alone. The study tracks tumor response, side effects, and how long the cancer is kept under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Savolitinib, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment option for people with a specific genetic type of metastatic colorectal cancer.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. Adding a drug can increase side effects, and the benefit over standard therapy is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changhai Hospital
Shanghai, 200000, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200000, China
-
Renji Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, 200000, China
-
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, 200000, China
-
Zhongshan Hospital, Fudan University
Shanghai, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- First-in-Class cancer drug targets Hard-to-Treat tumors
- New pill targets Hard-to-Treat cancers with a specific gene mutation
- AI eye on cancer: robot helps spot hidden polyps
- New hope for Hard-to-Treat colorectal cancer? drug combo trial launches
- New drug cocktail aims to fight metastatic colorectal cancer